Dow Up0.07% Nasdaq Up0.61%

Northwest Biotherapeutics, Inc. (NWBO)

5.40 Up 0.32(6.30%) Nov 26, 4:00PM EST
ProfileGet Profile for:
Northwest Biotherapeutics, Inc.
4800 Montgomery Lane
Suite 800
Bethesda, MD 20814
United States - Map
Phone: 240-497-9024

Index Membership:N/A
Full Time Employees:9

Business Summary 

Northwest Biotherapeutics, Inc., a development stage biotechnology company, discovers and develops immunotherapy products to treat cancers in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. The company’s products include DCVax-L, which is under Phase III brain cancer trial for treating brain and ovarian cancer; DCVax-Direct that is under Phase I/II clinical for various types of inoperable solid tumor cancers; and DCVax-Prostate for late stage hormone independent prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Northwest Biotherapeutics, Inc.

Corporate Governance 
Northwest Biotherapeutics, Inc.’s ISS Governance QuickScore as of Nov 1, 2014 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 9; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Ms. Linda F. Powers J.D., 59
Chairperson, Chief Exec. Officer, Pres, Chief Financial Officer and Principal Accounting Officer
Dr. Alton L. Boynton Ph.D., 70
Founder, Chief Scientific Officer, Sec. and Director
Dr. Marnix L. Bosch Ph.D., MBA, 54
Chief Technical Officer
Mr. Leslie J. Goldman , 69
Sr. VP of Bus. Devel.
Dr. Anthony E. Maida III, MA, MBA, Ph.D., 62
Sr. VP of Clinical Research
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders